Which has higher earnings and valuation, CGON or IMCR?

Immunocore has higher revenue and earnings than CG Oncology. Immunocore is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CG Oncology $4.04M 1,652.02 -$160.99M -$2.69 N/A Immunocore $400.02M 4.33 -$35.51M -$0.37 N/A

Is CGON or IMCR more profitable?

Immunocore has a net margin of -4.20% compared to CG Oncology's net margin of -3,602.68%. Immunocore's return on equity of -4.54% beat CG Oncology's return on equity. Company Net Margins Return on Equity Return on Assets CG Oncology -3,602.68% -26.58% -25.34% Immunocore -4.20% -4.54% -1.66%

Does the media prefer CGON or IMCR?

In the previous week, CG Oncology had 17 more articles in the media than Immunocore. MarketBeat recorded 29 mentions for CG Oncology and 12 mentions for Immunocore. Immunocore's average media sentiment score of 0.27 beat CG Oncology's score of 0.03 indicating that Immunocore is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 7 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Immunocore 2 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to IMCR or MIRM?

In the previous week, Mirum Pharmaceuticals had 23 more articles in the media than Immunocore. MarketBeat recorded 35 mentions for Mirum Pharmaceuticals and 12 mentions for Immunocore. Immunocore's average media sentiment score of 0.27 beat Mirum Pharmaceuticals' score of 0.11 indicating that Immunocore is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunocore 2 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Mirum Pharmaceuticals 6 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to XENE or IMCR?

In the previous week, Xenon Pharmaceuticals had 3 more articles in the media than Immunocore. MarketBeat recorded 15 mentions for Xenon Pharmaceuticals and 12 mentions for Immunocore. Xenon Pharmaceuticals' average media sentiment score of 0.65 beat Immunocore's score of 0.27 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Immunocore 2 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor IMCR or DNTH?

In the previous week, Dianthus Therapeutics had 23 more articles in the media than Immunocore. MarketBeat recorded 35 mentions for Dianthus Therapeutics and 12 mentions for Immunocore. Dianthus Therapeutics' average media sentiment score of 0.54 beat Immunocore's score of 0.27 indicating that Dianthus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunocore 2 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Dianthus Therapeutics 10 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media favor IMCR or LGND?

In the previous week, Ligand Pharmaceuticals had 15 more articles in the media than Immunocore. MarketBeat recorded 27 mentions for Ligand Pharmaceuticals and 12 mentions for Immunocore. Ligand Pharmaceuticals' average media sentiment score of 0.57 beat Immunocore's score of 0.27 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunocore 2 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Ligand Pharmaceuticals 7 Very Positive mention(s) 2 Positive mention(s) 13 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Immunocore (IMCR) Competitors

$34.08 +0.09 (+0.25%)

As of 11:33 AM Eastern

Compare

IMCR vs. CGON, MIRM, XENE, DNTH, and LGND

Should you buy Immunocore stock or one of its competitors? MarketBeat compares Immunocore with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Immunocore include CG Oncology (CGON), Mirum Pharmaceuticals (MIRM), Xenon Pharmaceuticals (XENE), Dianthus Therapeutics (DNTH), and Ligand Pharmaceuticals (LGND). These companies are all part of the "biotechnology" industry.

How does Immunocore compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and Immunocore (NASDAQ:IMCR) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

26.6% of CG Oncology shares are held by institutional investors. Comparatively, 84.5% of Immunocore shares are held by institutional investors. 4.8% of CG Oncology shares are held by insiders. Comparatively, 10.1% of Immunocore shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Immunocore has higher revenue and earnings than CG Oncology. Immunocore is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,652.02	-$160.99M	-$2.69	N/A
Immunocore	$400.02M	4.33	-$35.51M	-$0.37	N/A

In the previous week, CG Oncology had 17 more articles in the media than Immunocore. MarketBeat recorded 29 mentions for CG Oncology and 12 mentions for Immunocore. Immunocore's average media sentiment score of 0.27 beat CG Oncology's score of 0.03 indicating that Immunocore is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	7 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
Immunocore	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

CG Oncology has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market. Comparatively, Immunocore has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market.

CG Oncology presently has a consensus price target of $83.18, indicating a potential upside of 10.47%. Immunocore has a consensus price target of $57.29, indicating a potential upside of 68.07%. Given Immunocore's higher possible upside, analysts clearly believe Immunocore is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Immunocore	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.55

Immunocore has a net margin of -4.20% compared to CG Oncology's net margin of -3,602.68%. Immunocore's return on equity of -4.54% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	-3,602.68%	-26.58%	-25.34%
Immunocore	-4.20%	-4.54%	-1.66%

Summary

Immunocore beats CG Oncology on 12 of the 17 factors compared between the two stocks.

How does Immunocore compare to Mirum Pharmaceuticals?

Immunocore (NASDAQ:IMCR) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

84.5% of Immunocore shares are owned by institutional investors. 10.1% of Immunocore shares are owned by insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Mirum Pharmaceuticals had 23 more articles in the media than Immunocore. MarketBeat recorded 35 mentions for Mirum Pharmaceuticals and 12 mentions for Immunocore. Immunocore's average media sentiment score of 0.27 beat Mirum Pharmaceuticals' score of 0.11 indicating that Immunocore is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunocore	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Mirum Pharmaceuticals	6 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

Mirum Pharmaceuticals has higher revenue and earnings than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunocore	$400.02M	4.33	-$35.51M	-$0.37	N/A
Mirum Pharmaceuticals	$521.31M	12.27	-$23.36M	-$14.55	N/A

Immunocore presently has a consensus target price of $57.29, indicating a potential upside of 68.07%. Mirum Pharmaceuticals has a consensus target price of $137.33, indicating a potential upside of 39.43%. Given Immunocore's higher possible upside, equities analysts plainly believe Immunocore is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunocore	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.55
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Immunocore has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market.

Immunocore has a net margin of -4.20% compared to Mirum Pharmaceuticals' net margin of -139.18%. Immunocore's return on equity of -4.54% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunocore	-4.20%	-4.54%	-1.66%
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%

Summary

Immunocore beats Mirum Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Immunocore compare to Xenon Pharmaceuticals?

Xenon Pharmaceuticals (NASDAQ:XENE) and Immunocore (NASDAQ:IMCR) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

Xenon Pharmaceuticals has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market. Comparatively, Immunocore has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market.

Xenon Pharmaceuticals has a net margin of 0.00% compared to Immunocore's net margin of -4.20%. Immunocore's return on equity of -4.54% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-43.98%	-41.72%
Immunocore	-4.20%	-4.54%	-1.66%

95.5% of Xenon Pharmaceuticals shares are held by institutional investors. Comparatively, 84.5% of Immunocore shares are held by institutional investors. 2.9% of Xenon Pharmaceuticals shares are held by insiders. Comparatively, 10.1% of Immunocore shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Xenon Pharmaceuticals had 3 more articles in the media than Immunocore. MarketBeat recorded 15 mentions for Xenon Pharmaceuticals and 12 mentions for Immunocore. Xenon Pharmaceuticals' average media sentiment score of 0.65 beat Immunocore's score of 0.27 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenon Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunocore	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Xenon Pharmaceuticals currently has a consensus target price of $77.13, suggesting a potential upside of 21.85%. Immunocore has a consensus target price of $57.29, suggesting a potential upside of 68.07%. Given Immunocore's higher possible upside, analysts plainly believe Immunocore is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00
Immunocore	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.55

Immunocore has higher revenue and earnings than Xenon Pharmaceuticals. Immunocore is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	$7.50M	815.95	-$345.91M	-$4.74	N/A
Immunocore	$400.02M	4.33	-$35.51M	-$0.37	N/A

Summary

Xenon Pharmaceuticals beats Immunocore on 9 of the 17 factors compared between the two stocks.

How does Immunocore compare to Dianthus Therapeutics?

Immunocore (NASDAQ:IMCR) and Dianthus Therapeutics (NASDAQ:DNTH) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

Immunocore currently has a consensus price target of $57.29, indicating a potential upside of 68.07%. Dianthus Therapeutics has a consensus price target of $124.27, indicating a potential upside of 14.72%. Given Immunocore's higher probable upside, equities analysts plainly believe Immunocore is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunocore	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.55
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93

In the previous week, Dianthus Therapeutics had 23 more articles in the media than Immunocore. MarketBeat recorded 35 mentions for Dianthus Therapeutics and 12 mentions for Immunocore. Dianthus Therapeutics' average media sentiment score of 0.54 beat Immunocore's score of 0.27 indicating that Dianthus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunocore	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Dianthus Therapeutics	10 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

84.5% of Immunocore shares are owned by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are owned by institutional investors. 10.1% of Immunocore shares are owned by company insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Immunocore has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market. Comparatively, Dianthus Therapeutics has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market.

Immunocore has a net margin of -4.20% compared to Dianthus Therapeutics' net margin of -10,096.95%. Immunocore's return on equity of -4.54% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunocore	-4.20%	-4.54%	-1.66%
Dianthus Therapeutics	-10,096.95%	-22.53%	-21.55%

Immunocore has higher revenue and earnings than Dianthus Therapeutics. Immunocore is trading at a lower price-to-earnings ratio than Dianthus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunocore	$400.02M	4.33	-$35.51M	-$0.37	N/A
Dianthus Therapeutics	$2.04M	2,903.00	-$162.34M	-$4.15	N/A

Summary

Immunocore beats Dianthus Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Immunocore compare to Ligand Pharmaceuticals?

Immunocore (NASDAQ:IMCR) and Ligand Pharmaceuticals (NASDAQ:LGND) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability.

Ligand Pharmaceuticals has lower revenue, but higher earnings than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunocore	$400.02M	4.33	-$35.51M	-$0.37	N/A
Ligand Pharmaceuticals	$290.54M	19.97	$124.45M	$9.35	30.97

Ligand Pharmaceuticals has a net margin of 67.88% compared to Immunocore's net margin of -4.20%. Ligand Pharmaceuticals' return on equity of 20.06% beat Immunocore's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunocore	-4.20%	-4.54%	-1.66%
Ligand Pharmaceuticals	67.88%	20.06%	11.68%

84.5% of Immunocore shares are held by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are held by institutional investors. 10.1% of Immunocore shares are held by company insiders. Comparatively, 5.6% of Ligand Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Ligand Pharmaceuticals had 15 more articles in the media than Immunocore. MarketBeat recorded 27 mentions for Ligand Pharmaceuticals and 12 mentions for Immunocore. Ligand Pharmaceuticals' average media sentiment score of 0.57 beat Immunocore's score of 0.27 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunocore	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Ligand Pharmaceuticals	7 Very Positive mention(s)	2 Positive mention(s)	13 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immunocore presently has a consensus price target of $57.29, indicating a potential upside of 68.07%. Ligand Pharmaceuticals has a consensus price target of $336.57, indicating a potential upside of 16.23%. Given Immunocore's higher possible upside, equities analysts clearly believe Immunocore is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunocore	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.55
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

Immunocore has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market. Comparatively, Ligand Pharmaceuticals has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market.

Summary

Ligand Pharmaceuticals beats Immunocore on 13 of the 17 factors compared between the two stocks.

Get Immunocore News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMCR vs. The Competition

Export

Metric	Immunocore	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.74B	$3.71B	$7.03B	$12.96B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-92.27	9.06	269.91	24.87
Price / Sales	4.33	1,278.42	654.69	108.21
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	4.53	17.97	11.40	6.45
Net Income	-$35.51M	-$13.25M	$3.45B	$347.50M
7 Day Performance	5.10%	5.58%	3.66%	3.77%
1 Month Performance	6.68%	-1.60%	-0.49%	-0.40%
1 Year Performance	6.62%	61.32%	77.51%	23.55%

Immunocore Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMCR Immunocore	2.6561 of 5 stars	$34.09 +0.3%	$57.29 +68.1%	+6.3%	$1.74B	$400.02M	N/A	320	Earnings Report Analyst Forecast
CGON CG Oncology	2.2491 of 5 stars	$72.33 +4.6%	$81.73 +13.0%	+202.2%	$6.38B	$4.04M	N/A	61	Earnings Report Analyst Forecast Analyst Revision
MIRM Mirum Pharmaceuticals	2.9712 of 5 stars	$104.21 -0.4%	$143.40 +37.6%	+67.8%	$6.35B	$521.31M	N/A	140	Positive News Earnings Report Analyst Upgrade Analyst Revision
XENE Xenon Pharmaceuticals	2.7364 of 5 stars	$63.45 +1.9%	$77.20 +21.7%	+89.5%	$6.13B	$7.50M	N/A	210	Earnings Report Analyst Forecast Analyst Revision
DNTH Dianthus Therapeutics	2.1078 of 5 stars	$110.58 +4.3%	$117.82 +6.6%	+480.6%	$6.04B	$2.04M	N/A	80	Earnings Report Insider Trade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMCR) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immunocore (IMCR) Competitors

IMCR vs. CGON, MIRM, XENE, DNTH, and LGND

How does Immunocore compare to CG Oncology?

Summary

How does Immunocore compare to Mirum Pharmaceuticals?

Summary

How does Immunocore compare to Xenon Pharmaceuticals?

Summary

How does Immunocore compare to Dianthus Therapeutics?

Summary

How does Immunocore compare to Ligand Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMCR vs. The Competition

Immunocore Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immunocore (IMCR) Competitors

IMCR vs. CGON, MIRM, XENE, DNTH, and LGND

How does Immunocore compare to CG Oncology?

Do insiders and institutionals have more ownership in CGON or IMCR?

Which has higher earnings and valuation, CGON or IMCR?

Does the media prefer CGON or IMCR?

Which has more volatility & risk, CGON or IMCR?

Do analysts rate CGON or IMCR?

Is CGON or IMCR more profitable?

Summary

How does Immunocore compare to Mirum Pharmaceuticals?

Do insiders & institutionals believe in IMCR or MIRM?

Does the media refer more to IMCR or MIRM?

Which has better valuation and earnings, IMCR or MIRM?

Do analysts rate IMCR or MIRM?

Which has more volatility and risk, IMCR or MIRM?

Is IMCR or MIRM more profitable?

Summary

How does Immunocore compare to Xenon Pharmaceuticals?

Which has more volatility & risk, XENE or IMCR?

Is XENE or IMCR more profitable?

Do insiders and institutionals hold more shares of XENE or IMCR?

Does the media refer more to XENE or IMCR?

Do analysts recommend XENE or IMCR?

Which has preferable earnings and valuation, XENE or IMCR?

Summary

How does Immunocore compare to Dianthus Therapeutics?

Do analysts recommend IMCR or DNTH?

Does the media favor IMCR or DNTH?

Do insiders & institutionals have more ownership in IMCR or DNTH?

Which has more volatility and risk, IMCR or DNTH?

Is IMCR or DNTH more profitable?

Which has higher valuation and earnings, IMCR or DNTH?

Summary

How does Immunocore compare to Ligand Pharmaceuticals?

Which has stronger valuation and earnings, IMCR or LGND?

Is IMCR or LGND more profitable?

Do institutionals & insiders have more ownership in IMCR or LGND?

Does the media favor IMCR or LGND?

Do analysts rate IMCR or LGND?

Which has more volatility and risk, IMCR or LGND?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMCR vs. The Competition

Immunocore Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools